Cleveland Clinic researchers discover a new diet-associated gut-microbe metabolite linked to cardiovascular disease
Discovery could help explain why beta-blockers are effective in treating heart disease patients
Cleveland Clinic researchers in the US have identified a gut microbe-generated byproduct – phenylacetylglutamine (PAG) – that is linked to the development of cardiovascular diseases, including heart attack, stroke and death.
Phenylalanine is an amino acid found in many foods, including plant- and animal-based protein sources like meat, beans and soy. The researchers – led by Stanley Hazen, MD, PhD, chair of the Department of Cardiovascular & Metabolic Sciences in Lerner Research Institute and co-section head of Preventive Cardiology & Rehabilitation in the Miller Family Heart, Vascular & Thoracic Institute – found that when phenylalanine is broken down by microbes in the gut, it produces a byproduct (metabolite) that ultimately shows up in blood called phenylacetylglutamine (PAG) that contributes to heart disease.
“Over the past decade there has been an increasing amount of data to suggest that gut microbes play a role in health, especially as it relates to heart disease,” said Dr Hazen, who also directs the Cleveland Clinic Center for Microbiome and Human Health. “We found that blood levels of PAG contribute to cardiovascular disease risk in a couple of different ways.”
Analysing samples from more than 5,000 patients over three years revealed that elevated PAGln levels predicted subjects who went on to experience adverse cardiac events like heart attack and stroke in the future, and also in those with type 2 diabetes (an independent risk factor for cardiovascular disease). Animal model and microbe transplantation studies suggest the gut microbe-produced PAG can play an important role in driving cardiovascular diseases.
The researchers also analysed whole blood, platelet-rich plasma and isolated platelets from patient samples to understand how PAG affects cell processes. They then analyzed animal models of arterial injury to see how PAG induced cellular changes manifest into disease. Dr Hazen and his team found that PAG enhanced platelet reactivity and clotting potential, which increases the likelihood of blood clots, a major cause of adverse cardiac events like heart attack and stroke.
“Part of the reason we were so interested to have made this discovery is that we found that PAG binds to the same receptors as beta-blockers, which are drugs commonly prescribed to help treat cardiac diseases,” said Hazen.
Administering beta-blockers to animal models with elevated PAG was shown to reverse cardiovascular endpoints driven by PAG. Additionally, researchers found that using gene-editing technology or drugs to block PAG-receptor signalling significantly reduced clotting activity.
“We believe our findings suggest that some of the benefits of beta-blockers may be attributed to preventing PAG-related activity,” said Hazen. “Beta-blockers have been widely studied and are prescribed to many cardiac patients, but, to our knowledge, this is the first time that this mechanism has been suggested as an explanation for some of their benefits.”
Ina Nemet, PhD; Prasenjit Saha, PhD; and Nilaksh Gupta, PhD, are co-first authors of the present study, which was supported by the National Heart, Lung, and Blood Institute (part of the National Institutes
of Health) and the Leducq Foundation.